Sodium- glucose cotransporter inhibitors and the brain
https://doi.org/10.15829/2713-0177-2023-4-26
Abstract
Diabetes mellitus (DM) is associated with an increased risk of stroke and cognitive impairment. The problem of preventing cerebral disorders in diabetes has not been solved. The review presents current data on the place and role of sodium-glucose cotransporters (SGLTs) in the brain, whose receptors play an important role in ischemia-reperfusion injury of the brain and neurodegenerative changes. Modern studies on the cerebroprotective effects of hypoglycemic drugs – SGLT inhibitors – are presented and summarized.
About the Authors
K. V. Antonova
Research Center of Neurology
Russian Federation
Russian Federation
Dr. Sc. (Med.), leading researcher of the 1st neurological department
80 Volokolamskoe Shosse, Moscow 125367
M. M. Tashanyan
Research Center of Neurology
Russian Federation
Russian Federation
Dr. Sc. (Med.), corresponding member RAS, deputy Director for Research, Head of the 1st Neurological Department
80 Volokolamskoe Shosse, Moscow 125367
O. V. Lagoda
Research Center of Neurology
Russian Federation
Russian Federation
C. Sc. (Med.), neurologist of the highest category, senior researcher of the 1st neurological department
80 Volokolamskoe Shosse, Moscow 125367
T. S. Shishkina
Research Center of Neurology
Russian Federation
Russian Federation
resident
80 Volokolamskoe Shosse, Moscow 125367
I. M. Lovchev
Research Center of Neurology
Russian Federation
Russian Federation
resident
80 Volokolamskoe Shosse, Moscow 125367
References
1.
Review
For citations:
Antonova K.V., Tashanyan M.M., Lagoda O.V., Shishkina T.S., Lovchev I.M. Sodium- glucose cotransporter inhibitors and the brain. FOCUS. Endocrinology. 2023;4(4):42-51. (In Russ.) https://doi.org/10.15829/2713-0177-2023-4-26
Views:
348
Email this article 